Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Neutral 64.3%

Neg 0% Neu 64.3% Pos 0%

Citigroup analyst Patrick Donnelly maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $24 to $45.